Stander E, Lehka B, Carqueijeiro I, Cuello C, Hansson F, Jansen H
Commun Biol. 2023; 6(1):1197.
PMID: 38001233
PMC: 10673892.
DOI: 10.1038/s42003-023-05574-8.
Miller E, Scheidt K
Synthesis (Stuttg). 2022; 54(5):1217-1230.
PMID: 36187077
PMC: 9524398.
DOI: 10.1055/a-1684-2942.
Ikarashi Y, Sekiguchi K, Mizoguchi K
Curr Med Chem. 2017; 25(9):1036-1045.
PMID: 28322152
PMC: 5898036.
DOI: 10.2174/0929867324666170320114713.
McCarthy C, Farney T, Canale R, Alleman Jr R, Bloomer R
Nutr Metab Insights. 2013; 5:23-31.
PMID: 23882145
PMC: 3698474.
DOI: 10.4137/NMI.S8567.
Taylor J, Li Z, Yang H, Laughlin M, Terjung R
J Physiol. 2008; 586(6):1649-67.
PMID: 18218679
PMC: 2375691.
DOI: 10.1113/jphysiol.2007.149567.
Antiarrhythmic action of rilmenidine on adrenaline-induced arrhythmia via central imidazoline receptors in halothane-anaesthetized dogs.
Mammoto T, Kamibayashi T, Hayashi Y, Yamatodani A, Takada K, Yoshiya I
Br J Pharmacol. 1996; 117(8):1744-8.
PMID: 8732285
PMC: 1909557.
DOI: 10.1111/j.1476-5381.1996.tb15348.x.
Receptor inhibition by immunoglobulins: specific inhibition by autistic children, their relatives, and control subjects.
Cook Jr E, Perry B, Dawson G, Wainwright M, Leventhal B
J Autism Dev Disord. 1993; 23(1):67-78.
PMID: 8463203
DOI: 10.1007/BF01066419.
3H-Rauwolscine binding in platelets from depressed patients and healthy volunteers.
Pimoule C, Briley M, Gay C, Loo H, Sechter D, Zarifian E
Psychopharmacology (Berl). 1983; 79(4):308-12.
PMID: 6407043
DOI: 10.1007/BF00433407.
Characteristics of the [3H]-yohimbine binding on rat brain alpha2-adrenoceptors.
Rouot B, Quennedey M, Schwartz J
Naunyn Schmiedebergs Arch Pharmacol. 1982; 321(4):253-9.
PMID: 6300700
DOI: 10.1007/BF00498509.
A study of the sensitivity of rat brain alpha 2-adrenoceptors during chronic antidepressant treatments.
SUGRUE M
Naunyn Schmiedebergs Arch Pharmacol. 1982; 320(2):90-6.
PMID: 6289141
DOI: 10.1007/BF00506306.
Interaction of the component enantiomers of the putative dopamine autoreceptor agonist, TL-99 (6,7-dihydroxy-2-dimethylamino tetralin) with dopaminergic systems in mammalian brain and teleost retina.
Williams M, Martin G, McClure D, Baldwin J, Watling K
Naunyn Schmiedebergs Arch Pharmacol. 1983; 324(4):275-80.
PMID: 6141532
DOI: 10.1007/BF00502623.
Evidence for pharmacological similarity between alpha 2-adrenoceptors in the vas deferens and central nervous system of the rat.
Doxey J, Gadie B, Lane A, Tulloch I
Br J Pharmacol. 1983; 80(1):155-61.
PMID: 6140052
PMC: 2044981.
DOI: 10.1111/j.1476-5381.1983.tb11061.x.
Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
Chang R, Lotti V
Proc Natl Acad Sci U S A. 1986; 83(13):4923-6.
PMID: 3014520
PMC: 323856.
DOI: 10.1073/pnas.83.13.4923.
Lesioning of serotoninergic and noradrenergic nerve fibres of the rat brain does not decrease binding of 3H-clonidine and 3H-rauwolscine to cortical membranes.
Gross G, Gothert M, Glapa U, Engel G, SCHUMANN H
Naunyn Schmiedebergs Arch Pharmacol. 1985; 328(3):229-35.
PMID: 2984581
DOI: 10.1007/BF00515546.
Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor.
Thomas D, Nelson D, Johnson A
Psychopharmacology (Berl). 1987; 93(2):193-200.
PMID: 2962217
DOI: 10.1007/BF00179933.
[3H]L-654,284 as a probe of the central alpha 2 adrenoceptor.
RANDALL W, Huff J, Vacca J, Guare J, Chen R, Rosegay A
Naunyn Schmiedebergs Arch Pharmacol. 1988; 338(1):47-52.
PMID: 2907099
DOI: 10.1007/BF00168811.
Pharmacological profile of a new potent and specific alpha 2-adrenoceptor antagonist, L-657,743.
Pettibone D, Clineschmidt B, Lotti V, Baldwin J, Huff J, RANDALL W
Naunyn Schmiedebergs Arch Pharmacol. 1987; 336(2):169-75.
PMID: 2891039
DOI: 10.1007/BF00165801.
Agonist binding at alpha 2-adrenoceptors of human platelets using 3H-UK-14,304: regulation by Gpp(NH)p and cations.
Schloos J, Wellstein A, Palm D
Naunyn Schmiedebergs Arch Pharmacol. 1987; 336(1):48-59.
PMID: 2888026
DOI: 10.1007/BF00177750.
L-654,284 a new potent and selective alpha 2-adrenoceptor antagonist.
Pettibone D, Clineschmidt B, Lotti V, Martin G, Huff J, RANDALL W
Naunyn Schmiedebergs Arch Pharmacol. 1986; 333(2):110-6.
PMID: 2875395
DOI: 10.1007/BF00506512.
Comparison of potency of alpha 2-adrenoceptor antagonists in vitro: evidence for heterogeneity of alpha 2-adrenoceptors.
Alabaster V, Keir R, Peters C
Br J Pharmacol. 1986; 88(3):607-14.
PMID: 2874857
PMC: 1916968.
DOI: 10.1111/j.1476-5381.1986.tb10241.x.